Paper Review Records
All Paper Review Records
22 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
82
days
Dynamics of in vivo immune remodeling in Ph + all patients receiving frontline ponatinib and blinatumomab therapy
Authors
Nadia Peragine; Michela Ansuinelli; Giulia Radice; Mariangela Di Trani; Maria Stefania De Propris; Giada Almici; Marina Parisi; Maria Paola Martelli; Daniele Mattei; Erika Borlenghi; Federico Fazio; Daniele Vallisa; Sabina Chiaretti; Anna Guarini; Robin FoàShow moreShow less
Affiliations
1. Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy; 2. Division of Hematology and Bone Marrow Transplant, Azienda Ospedaliera-Universitaria (AOU) Policlinico-S. Marco, Catania, Italy; 3. Dipartimento di Medicina e Chirurgia, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy; 4. Division of Hematology, Santa Croce e Carle Hospital, Cuneo, Italy; 5. Hematology, ASST Spedali Civili, Brescia, Italy; 6. Hematology, Azienda Ospedaliera-Universitaria SS. Arrigo e Biagio e Cesare Arrigo, Alessandria, Italy; 7. Hematology Unit, Department of Oncology and Hematology, Guglielmo da Saliceto Hospital, Piacenza, ItalyShow moreShow less
80
days
Hair bulb and oral mucosa DNA for prompt germline testing in hematologic neoplasms
Authors
Ferran Balbastre-Úbeda; Sara Torres-Esquius; Maria Gabarrós-Subirà; Francisco Beas; Jordi Leno-Colorado; Cristina Sanchez-Morales; Tzu Hua Chen-Liang; Susana Urban-Giral; Meritxell Tena-Alegre; Ana María Hurtado; María Jesús Casas-Tio; Ana María Garrido; Pamela Acha; Adoración Blanco; Francesc Solé; Mónica Del Rey; María Díez-Campelo; David Valcárcel; Maria Julia Montoro; Andrés JerezShow moreShow less
Affiliations
1. Myeloid Malignancies Research Group, Vall d’Hebron Institute of Oncology (VHIO), Hematology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 2. Clinical and Molecular Genetics Area, Vall d’Hebron Hospital Medicine Genetics Group, Vall d’Hebron Research Institute (VHIR), Barcelona, Spain; 3. Hematology Department, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Murcia, Spain; 4. Group of Genetics, Molecular Pathology and Rare Diseases, Health Sciences Faculty, Universidad Católica de Murcia, Guadalupe, Spain; 5. MDS Group, Josep Carreras Leukaemia Research Institute, ICO-Hospital Germans Trias i Pujol, Badalona, Spain; 6. Hematology Department, Hospital Universitario de Salamanca, Salamanca, SpainShow moreShow less
109
days
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity
Authors
Kenneth JC Lim; Melinda Tan; Ricardo Parrondo; Saurabh Chhabra; Christoph Schaefers; Katharine Dooley; Andre De Menezes Silva Corraes; Malvika Gupta; Darin Carabenciov; Morie Gertz; Lisa Hwa; Stephens Haily; Prashant Kapoor; Taxiarchis Kourelis; Rahma Warsame; Joselle Cook; Moritz Binder; Nadine Abdallah; Saurabh Zanwar; P. Leif Bergsagel; Udit Yadav; Erin Wiedmeier-Nutor; Susan Geyer; Sikander Ailawadhi; Rafael Fonseca; Shaji Kumar; Anastasia Zekeridou; Yi LinShow moreShow less
Affiliations
1. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, USA; 2. Australian Centre for Blood Diseases, Monash University, Melbourne, Australia; 3. Department of Haematology, The Alfred Hospital, Melbourne, Australia; 4. Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, USA; 5. Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, USA; 6. Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, USAShow moreShow less
107
days
Post-transplant hypomethylating agents plus venetoclax maintenance improves survival in high-risk myeloid malignancies: A matched cohort study
Authors
Haley Thigpen; Kendall Diebold; Todd Mudd; Maris Hardee; Manuel Espinoza-Gutarra; Antonio Di Stasi; Donna Salzman; Razan Mohty; Jorge Cortes; Ravi Bhatia; Omer JamyShow moreShow less
Affiliations
1. Department of Medicine, University of Alabama at Birmingham, Birmingham, USA; 2. Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, USAShow moreShow less
19
days
Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the making
Authors
Hagop Kantarjian; Ayalew TefferiShow moreShow less
Affiliations
1. Department of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, USA; 2. Mayo Clinics, Rochester, USAShow moreShow less
203
days
Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma
Authors
Lawrence Liu; Byron Sigel; Mei Wang; Nikhil Grandhi; Martin W. Schoen; Kristen M. Sanfilippo; Kenneth R. Carson; Murali Janakiram; Tzeyu L. Michaud; Graham A. Colditz; Theodore S. Thomas; Su-Hsin ChangShow moreShow less
Affiliations
1. Research Service, St. Louis Veterans Affairs Medical Center, St. Louis, USA; 2. Department of Hematology/Oncology, Cedars-Sinai Medical Center, Los Angeles, USA; 3. Department of Medicine, Washington University School of Medicine, St. Louis, USA; 4. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, USA; 5. The University of Texas MD Anderson Cancer Center, Houston, USA; 6. Division of Hematology and Medical Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, USA; 7. Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, USA; 8. Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, USA; 9. Department of Health Promotion, College of Public Health, University of Nebraska Medical Center, Omaha, USAShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days